Vera Therapeutics 경영진
경영진 기준 점검 3/4
현재 CEO에 대한 정보가 충분하지 않습니다.
핵심 정보
Marshall Fordyce
최고경영자
US$7.0m
총 보수
| CEO 급여 비율 | 9.45% |
| CEO 재임 기간 | 10yrs |
| CEO 지분 보유율 | 0.4% |
| 경영진 평균 재임 기간 | 2.1yrs |
| 이사회 평균 재임 기간 | 5.6yrs |
최근 경영진 업데이트
Recent updates
Seeking Alpha • Feb 20
Vera Therapeutics: Hold Rating Based On Potential For Atacicept In IgAN (Rating Downgrade)
Summary Vera Therapeutics is downgraded from 'Strong Buy' to 'Hold' due to intensifying competition in the IgAN space. VERA's atacicept met the primary endpoint in the phase 3 ORIGIN trial, enabling a BLA submission and Priority Review with a PDUFA date of July 7, 2026. Competitive risks are heightened by Otsuka's VOYXACT, which shows superior proteinuria reduction and more convenient dosing. VERA maintains strong liquidity with $779M pro forma cash and additional non-dilutive capital but faces pivotal eGFR data risk in 2027. Read the full article on Seeking Alpha분석 기사 • Jun 27
Is Vera Therapeutics (NASDAQ:VERA) Weighed On By Its Debt Load?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...분석 기사 • Mar 14
Is Vera Therapeutics (NASDAQ:VERA) Weighed On By Its Debt Load?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Seeking Alpha • Mar 07
Vera Therapeutics: Does The Earlier Otsuka Launch Harm Its Prospects Much?
Summary Vera stock dropped after Otsuka announced plans for accelerated approval of sibeprenlimab, but analysts believe the selloff was an overreaction. Atacicept is more disease-modifying, while sibeprenlimab offers better immediate kidney protection; both have comparable safety profiles. Sibeprenlimab may hit the market 6 months earlier than atacicept, but complementary actions in IgAN suggest minimal impact on atacicept. VERA's financials are strong with a cash runway of 10 quarters, but the lack of phase 3 uPCR data remains a key risk. Read the full article on Seeking AlphaSeeking Alpha • Dec 22
Vera Therapeutics: Strong Data In IgAN, But We May Be Too Late
Summary Vera Therapeutics' Atacicept has shown promising results in IgA nephropathy (IgAN), leading to significant stock gains and differentiating it from competitors by preserving kidney function. The phase 2b ORIGIN trial met primary and secondary endpoints, demonstrating reductions in proteinuria and stabilization of eGFR, with a phase 3 trial ongoing. Financially, Vera has a strong cash position with a market cap of $2.6bn and a cash runway of over 12-14 quarters. Despite the positive data, I remain cautious about entering the stock now due to its strong current trading levels. Read the full article on Seeking Alpha분석 기사 • Oct 07
Is Vera Therapeutics (NASDAQ:VERA) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Seeking Alpha • Oct 04
Vera: Potential First Of Atacicept As A B-Cell Modulator For IgAN Patients
Summary Vera Therapeutics, Inc. topline 36-week data from the phase 3 ORIGIN study, using Atacicept for the treatment of patients with IgA Nephropathy, expected Q2 of 2025. 96-week data from the phase 2 ORIGIN study, using Atacicept for the treatment of patients with IgA Nephropathy, expected at ASN Kidney week oral presentation October 23–27 2024. The global IgA Nephropathy market is expected to reach $41.24 billion by 2033. Possible expansion opportunities would include targeting other IgAN subpopulations like anti-PLA2R and anti-nephrin podocytopathies; Along with using the drug for rheumatological and hematological indications. Read the full article on Seeking AlphaSeeking Alpha • Jul 22
Vera Therapeutics' Atacicept: A Potential Game-Changer In IgA Nephropathy
Summary Vera Therapeutics is advancing atacicept, a treatment for IgA nephropathy, now in a pivotal Phase 3 trial after promising Phase 2 results. Atacicept has shown potential for significantly reducing proteinuria and stabilizing kidney function with minimal side effects. The drug faces competition from other APRIL and BAFF inhibitors and a recently approved therapy, sparsentan. Despite the competition and market risks, the investment recommendation is to maintain a "Buy" on Vera, given the promising data and upcoming trial results. Read the full article on Seeking Alpha분석 기사 • Jul 05
Is Vera Therapeutics (NASDAQ:VERA) Using Debt In A Risky Way?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Seeking Alpha • Jan 25
Vera Therapeutics: Soaring On IgAN Data, But Full Approval A Distant Prospect
Summary Vera Therapeutics, Inc. stock price soared over 35% today as it announced positive results from the open label extension of its Phase 2b ORIGIN clinical trial for atacicept in IgA nephropathy. The company's stock is up over 160% in the past year and is trading at its highest value since late 2021. Vera's CEO believes that atacicept has the potential to be a disease-modifying treatment for IgA nephropathy, and the ongoing Phase 3 trial is progressing well. The competition in igAN has been intensifying, however, and with no approval expected until 2025, Vera's stock price looks a little vulnerable in the short term. Short interest recently climbed >20%. Read the full article on Seeking AlphaSeeking Alpha • Sep 06
Vera Therapeutics: Under The Radar IgAN Player Has Much To Prove
Summary Shares have risen by 67% since May 2021 IPO. IgA Nephropathy is an increasingly attractive opportunity that multiple companies are targeting given regulatory tailwinds. Atacicept's unique value proposition is to target IgAN upstream (turn off the faucet) and strong observational data links lowering Gd-IgA1 levels to improved proteinuria. MAU868 for BK Viremia is thought to have broad potential as a prophylactic agent but I think it's a niche product at best. I cannot recommend VERA at this time and believe near-term burden of proof rests on ORIGIN phase 2b data in 2023. Shares of Vera Therapeutics (VERA) have risen by 67% since IPO priced at $11 back in May of 2021. So far in 2022, share price has fallen by almost 30%. I grew interested in this early-stage player in immunological disease space as I researched multiple Iga nephropathy (IgAN) contenders in what I consider to be an increasingly lucrative area with multiple tailwinds (see my recent article on Chinook Therapeutics which also provides a view of the overall landscape). Specifically, the FDA's willingness to accept surrogate endpoints such as proteinuria reduction for regulatory approval is speeding up development timelines and several promising drugs could improve outcomes for these patients in the next few years. Vera's dual inhibitor of BLyS and APRIL, atacicept, could have best-in-class potential for IgAN and has an important readout coming up in Q1 2023. Couple that with additional shots on goal in lupus nephritis and other indications of high unmet need, at a current enterprise value of just $400M, and it's clear why I wanted to dig deeper and see if there's a near term opportunity for my readers. Chart FinViz Figure 1: VERA weekly chart (Source: Finviz) When looking at charts, clarity often comes from taking a look at distinct time frames in order to determine important technical levels and get a feel for what's going on. In the weekly chart above, we can see shares bounce around in the $15 to $30 range for much of the past year. After bottoming in mid-teens this summer, they've again rebounded just south of $20 and appear to be consolidating for a move higher still. My initial take is that, given tailwinds to the IgAN space and presence of a near term catalyst coming up, investors interested in this story would do well to establish a pilot position and from there accumulate dips in Q3 for the potential run-up into data in 2023. Overview Founded in 2016 with headquarters in San Francisco (just 17 full-time employees), Vera Therapeutics currently sports enterprise value of ~$400M and Q2 cash position of $131M providing them operational runway for roughly 1.5 years (conservatively). At Wedbush PacGrow Healthcare Conference presentation, CEO Marshall Fordyce describes the company as developing novel medicines in the area of immune-related kidney disease where there is large unmet need and market opportunity with recent favorable regulatory conditions. Vera has 3 programs in late-stage clinical development (impressive for a small company). Corporate Slides Figure 2: Pipeline & milestones (Source: corporate presentation) Atacicept is their lead candidate, a fusion protein that is dosed once per week subcutaneously and previously has been in over a thousand patients in clinical studies (well-characterized safety and manufacturing profile). Atacicept was actually phase 3-ready when Vera licensed the drug in from Merck KGaA. Vera is developing it for two immune-driven kidney diseases, IgAN and lupus nephritis. IgAN is an autoimmune disease of the kidney affecting young people (average age of diagnosis at age 30). It's now getting attention from developers but has no disease-modifying drugs. They estimate the market to be at least in the high single digit billions in the US alone and there is emerging evidence that targeting the source of the disease (B cells which produce bad-acting auto antibodies in IgAN) could be disease-modifying and substantially improve kidney function as measured by protein in the urine and GFR. No one has shown this mechanism leads to improved kidney function in multi-national, randomized controlled studies yet and Vera hopes to be the first. Corporate Slides Figure 3: Atacicept hits two steps in the pathogenesis of IgAN (Source: corporate presentation) Atacicept targets B cell lineage through dual inhibition of APRIL and BLyS which potentially makes it more potent and confers dosing advantages versus APRIL only approach. Readout of phase 2b ORIGIN study is due in early Q1 of 2023 and will demonstrate the effect of atacicept on kidney function as measured by proteinuria as primary endpoint. These results could be very meaningful for the field. Second upcoming milestone is for lupus nephritis, as they have agreement with FDA to advance the higher dose (150mg) into a phase 3 study to be initiated this year. Third, they are developing a second molecule, MAU868, for BK virus which is a leading cause of kidney failure in transplant patients. There are no approved drugs here and they have the first results of a randomized, controlled-study showing that this neutralizing antibody can reduce BK virus in the blood versus placebo. Company has lean operating model, completely focused on clinical development and leadership team comes from Gilead and Genentech (highly experienced with drug approvals that led to blockbuster sales). Returning to IgAN, the market is quickly evolving with much more interest coming into the space. Diagnosis is done by kidney biopsy and there is reason to believe IgAN is underdiagnosed. Prior, physicians knew with diagnosis they would just give patients an angiotensin receptor blocker or ACE inhibitor if they know the patient does not have diabetes or high blood pressure driving kidney failure. Diagnosis as a kidney biopsy is still a hurdle. There are two biomarkers that track with disease severity, the bad-acting auto-antibodies (GD-IgA1) which can be assayed and IgG. Together the two may have strong specificity for diagnosis and there are efforts to bring those forward as a non-invasive approach to diagnosis. Atacicept is the first and only molecule in development to show reduction in these biomarkers in randomized, controlled trials. Hepatitis C market was a great example of how when effective therapies come along, diagnosis goes up. IgAN patients traditionally have had no treatments available except ACE inhibitors or steroids, and randomized studies for the latter have been stopped early due to known acute and chronic side effects. Tarpeyo is now approved in IgAN and it is a reformulated steroid that provides a marginal improvement. Natural history data shows that 30% reduction in proteinuria leads to improved kidney outcomes over time, and that's why Tarpeyo received accelerated approval (and potentially provides tailwind for all IgAN developers). CEO views upcoming approvals of endothelial receptor antagonists Chinook Therapeutics' (KDNY) atrasentan and Travere Therapeutics' (TVTX) sparsentan as potential improvements on ACE inhibitors or ARBs (protecting the kidney through hemodynamic change). Again, none of these approaches are disease-modifying and work downstream of this disease process. As it stands, there is strong observational data linking lowering Gd-IgA1 to improve proteinuria and leads to improved clinical outcomes including mortality and time to dialysis. However, how this translates into regulatory handling of specific programs is all conjecture at this point (too premature). Corporate Slides Figure 4: High Gd-IgA1 associated with reduced time to dialysis, transplant and death (Source: corporate presentation) For the ORIGIN phase 2b study in IgAN, they are looking for data in early 2023 (24-week assessment). Atacicept prior has been studied in a small, randomized controlled study of about 15 patients (similar population) where it showed clear reduction (60%) in Gd-IgA1 at the middle dose (75 mg). CEO considered that to be pretty compelling and they will see whether they can meet or exceed that reduction in the ORIGIN study. They did see reduction in proteinuria, but again with wide error bars because numbers were small (27.7% reduction in proteinuria at 24 weeks). ORIGIN was designed for that reason, to get a better idea of the true reduction in proteinuria they can achieve including at high dose of 150mg. Study is powered for at least a 28% reduction in proteinuria (threshold is 30%, which led to accelerated approval for Tarpeyo). Corporate Slides Figure 5: Competitor landscape in IgAN (Source: corporate presentation) They will be showing delta from placebo (prior trial had outlier that created increase in proteinuria in placebo, whereas placebo arm in ORIGIN study is expected to have no change in proteinuria at 24 weeks). 150mg dose will also be used in the lupus nephritis study. Merck was looking at taking the asset originally into systemic lupus, then they decided to focus pipeline elsewhere. Formerly, exposure safety analysis run by Merck was given a thumbs up to take 150mg dose into LN. However, dosing higher does not make sense as they do see a plateau in other disease sets (appear to be on the plateau when they go from 75mg to 150mg). Target product profile is appealing and simple, one mL subcutaneously once per week (what Humira is, for example). They are in a unique position as they know safety data in over 1000 patients. Base case is that they will have to run a phase 3 study after this phase 2b trial. ORIGIN study will be followed out to 96 weeks as long-term results are important (want to push possibility of dialysis further out into the future for these patients who are 30 years old on average at diagnosis). The hypothesis is that this drug is having a broader renal impact (removing the bad-acting auto-antibody so that downstream effects may be lessened). Mechanism will be key and again it depends on what alternatives are available (down to efficacy, safety and tolerability). They anticipate atacicept being used as a chronic, maintenance therapy (envision other mechanisms that have shorter duration, like Tarpeyo label which includes 9 months). Moving on to lupus nephritis, there were no approved drugs 2 years ago and it is a terrible disease with huge unmet need. It can have a form where it causes rash, affects joints and can also be organ-threatening (lead to stroke or kidney failure). Brain fog, fatigue and other symptoms are quite difficult to measure in a multi-national study. There are now two approved drugs in LN (voclosporin from Aurinia and Benylsta from GSK) on basis of complete renal response endpoint (lab measures of protein in urine and GFR stability). Now, there is a precedent for approvals with this endpoint and nice correlation between phase 2 and phase 3. Vera wants to see this for indications they choose for development. It looks like atacicept can be efficacious in LN, and data in subset of patients with severe disease looks promising. Primary endpoint is 52 weeks (mimics voclosporin program). BLyS only is an approved drug for LN and systemic lupus (Benlysta), and we can think of atacicept as BLyS plus X (think adding APRIL to that mechanism can perform better in a randomized, controlled study). Prior data for atacicept has shown it reduced disease-associated auto-antibodies (dose-responsive) and suggest it potentially could work. Corporate Presentation Figure 6: Phase 2 evidence of clinical efficacy in SLE (Source: corporate presentation) As for MAU868 in BK virus, I remind readers that the company acquired this asset from Amplyx Pharmaceuticals (subsidiary of Pfizer) in December of last year for a mere $5M upfront payment in addition to $7M in certain regulatory milestones and low single digit percentage royalties on net sales. Vera is also obligated to make certain milestone payments in an aggregate amount of up to $69M to Amplyx' partner Novartis as well as mid-to-high single-digit percentage royalties. At the time, Vera also entered into a credit facility with Oxford Finance of up to $50M (drew the $5M upfront payment at closing) and debt facility provides for at least 48-months of interest only payments. MAU868 has the potential to neutralize infection by blocking BKV virions from binding to host cells. CEO Marshall Fordyce notes that BK is a leading cause of kidney transplant loss and transplant-associated morbidity, with no currently available antiviral treatments in the US and potential to significantly impact outcomes for these kidney transplant patients (provide a new standard of care). Up to 90 percent of healthy adults are infected with BKV, but it remains latent in kidney and bladder tissues. Reactivation occurs in the setting of immune suppression, and causes clinical disease in the transplant setting. BKV is a significant cause of complications in immunocompromised patients, including in kidney transplant and hematopoietic stem cell transplant (HSCT) recipients. In kidney transplant recipients, BKV is a leading cause of allograft loss and poor outcomes, while in HSCT recipients, the virus significantly increases the risk of severe hemorrhagic cystitis, which causes bladder damage. Corporate Slides Figure 7: BKV is a leading cause of allograft loss (Source: corporate presentation) Positive interim phase 2 data was reported in June, showing that MAU868 was well tolerated and demonstrated significant BK antiviral activity in kidney transplant recipients with BK viremia. Corporate Slides Figure 8: Antiviral and renal effect versus placebo at week 12 (Source: corporate presentation) Playing devil's advocate, I think given details of the deal including low upfront payment, perhaps the market assigns little to no value to this asset until a phase 3 win is achieved or even a regulatory green light. Other Information For the second quarter of 2022, the company reported cash and equivalents of $131.9M (along with access to $45M credit facility) as contrasted to net cash used in operating activities for past six months of $28M (nearing triple the prior year). Quarterly net loss was $14.9M. My estimation is that the company (conservatively) has operational runway of 2 years with current resources at its disposal, so I would not be surprised to see further dilution via secondary offering by mid 2023 or so. Accumulated deficit so far is a reasonable $124.1M. As for prior financings, I consider it a green flag that February's upsized offering took place at $15/share (nearly 30% lower than current levels). For those wanting to learn more about the value proposition behind MAU868, the March webinar was quite helpful for me. Here are a few nuggets: Patients undergo kidney transplant and then put under immune suppression can have reactivation of BK virus that threatens survival of their transplanted kidney. This is a major clinical problem (risk to their new kidney), although BK Virus nephropathy is not a well-known disease. Dr. Jordan, the Director of Nephrology and Transplant Immunology at Cedars-Sinai, states that BK Virus is an opportunistic infection associated with significant morbidity and mortality in transplant patients. Virus finds a home, is dormant and in immuno-suppressed patients is reactivated, starts killing the graft cells and eventually kills the kidney. Main risk factor is overall degree of immunosuppression. Mainstay of management at this time is reducing immunosuppression which has deleterious side effect of increasing risk for rejection. 100,000 kidney transplants are done worldwide each year. Reactivation occurs in about 40% of these patients (virus starts appearing in the urine and if it persists, it appears in the blood). If it persists, you know you are going to get damage to the kidney (kidney function can deteriorate rapidly). If physician resorts to lowering immunosuppression (current standard of care), 12% of patients have rejection of organ (KOL thinks in his experience it's much more than 12%). Devil's advocate, again 12% would seem like a low percent overall and I'm still not sure the market potential for such an asset, not to mention adoption that would occur IF it is approved. On the other hand, data shows that standard of care (immunosuppression reduction) is not a good idea in many cases as it could allow patient's kidney to be rejected by the immune system. MAU868 neutralizes all four genotypes of BK Virus at subnanomolar concentrations. This mechanism of neutralization is proven and effective as seen in other approved monoclonal antibody therapies. In vitro it has been shown to be more potent than IVIG. Administration could be to patients before evidence of BKV replication in plasma as prophylaxis, preemptively at early stages of BKV infection or after disease diagnosis in treatment perspective. Optimal positioning may be in prophylactic high-risk patient or preemptively. As for institutional investors of note, Longitude Capital Partner owns a 12.7% stake and RA Capital owns a 7.5% stake. As for insiders, CEO Marshall Fordyce owns 181,500 shares but constant insider sells over the past few months are not inspiring confidence. As for relevant leadership experience, Chief Medical Officer Celia Lin served prior as Senior Medical Director at Genentech (responsible for phase 3 global study execution and regulatory filing in orphan disease). Chief Development Officer Joane Curley prior led Project and Portfolio Management at Gilead Sciences. Similarly, SVP Development Operations Tom Doan also came from Gilead where he served as Executive Director, Clinical Operations Head of the Inflammation/Respiratory Therapeutic Area.Seeking Alpha • Aug 10
Vera Therapeutics GAAP EPS of -$0.55 beats by $0.17
Vera Therapeutics press release (NASDAQ:VERA): Q2 GAAP EPS of -$0.55 beats by $0.17. cash, cash equivalents, and marketable securities as of $131.9M분석 기사 • Feb 16
Companies Like Vera Therapeutics (NASDAQ:VERA) Are In A Position To Invest In Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Seeking Alpha • Jan 19
Vera: Biotech With 3 Mid-Stage Programs With Potential For Success
Results from the phase 2 study using MAU868 for the treatment of patients with the BK virus are expected by mid-2022. Results from the phase 2b ORIGIN study using atacicept for the treatment of patients with IgA Nephropathy are expected by Q4 of 2022. A phase 3 study was initiated using atacicept for the treatment of patients with lupus nephritis. The global lupus nephritis market is estimated to be worth $3.1 billion by 2027.Seeking Alpha • Jan 07
Vera Therapeutics: Surprising Pivot To A Kidney Disease Drug Looks Like A Long Shot
Vera Therapeutics was formerly Trucode Gene Repair, before management took an opportunity to repurpose a 20-year-old autoimmune drug. Acquired from Merck KgAA, Atacicpet showed in a trial of 15 patients that it could reduce Gd-IgA1 by 60% in patients with IgAN - a kidney disease. The drug has a unique mechanism of action with dual inhibiting qualities which makes it a contender for approval in an underserved space. Several other companies are targeting the space however and one has already succeeded - the true value is measured in eGFR, rather than proteinuria. Vera has a second asset targeting the BK Virus in kidney transplant patients. Both assets are long shots, but management is experienced, making Vera an intriguing investment case - but probably a little too risky.분석 기사 • Oct 25
We Think Vera Therapeutics (NASDAQ:VERA) Can Afford To Drive Business Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...CEO 보수 분석
| 날짜 | 총 보수 | 급여 | 회사 수익 |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$369m |
| Dec 31 2025 | US$7m | US$660k | -US$300m |
| Sep 30 2025 | n/a | n/a | -US$252m |
| Jun 30 2025 | n/a | n/a | -US$218m |
| Mar 31 2025 | n/a | n/a | -US$175m |
| Dec 31 2024 | US$6m | US$616k | -US$152m |
| Sep 30 2024 | n/a | n/a | -US$134m |
| Jun 30 2024 | n/a | n/a | -US$108m |
| Mar 31 2024 | n/a | n/a | -US$94m |
| Dec 31 2023 | US$3m | US$586k | -US$96m |
| Sep 30 2023 | n/a | n/a | -US$103m |
| Jun 30 2023 | n/a | n/a | -US$107m |
| Mar 31 2023 | n/a | n/a | -US$102m |
| Dec 31 2022 | US$4m | US$551k | -US$89m |
| Sep 30 2022 | n/a | n/a | -US$73m |
| Jun 30 2022 | n/a | n/a | -US$56m |
| Mar 31 2022 | n/a | n/a | -US$45m |
| Dec 31 2021 | US$1m | US$479k | -US$33m |
| Sep 30 2021 | n/a | n/a | -US$59m |
| Jun 30 2021 | n/a | n/a | -US$55m |
| Mar 31 2021 | n/a | n/a | -US$56m |
| Dec 31 2020 | US$3m | US$360k | -US$53m |
보상 대 시장: Marshall의 총 보수(USD6.99M)는 US 시장에서 비슷한 규모 기업의 평균(USD7.05M) 수준입니다.
보상과 수익: Marshall의 보상은 회사가 적자임에도 증가했습니다.
CEO
Marshall Fordyce (50 yo)
10yrs
재임 기간
US$6,986,410
보수
Dr. Marshall W. Fordyce, M.D. is Founder of Vera Therapeutics, Inc. and has been its President, Chief Executive Officer and Director since May 2016. From April 2011 to July 2016, Dr. Fordyce held a number...
리더십 팀
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| Founder | 10yrs | US$6.99m | 0.43% $ 10.7m | |
| Chief Financial Officer | 4.8yrs | US$2.72m | 0.086% $ 2.1m | |
| Chief Opearating Officer | 1.8yrs | US$2.72m | 0.0088% $ 217.0k | |
| Chief Medical Officer | 2.3yrs | US$2.72m | 0.0095% $ 233.8k | |
| Chief Regulatory Officer | 2.3yrs | US$2.35m | 0.0048% $ 118.1k | |
| Senior VP of Finance & Chief Accounting Officer | 5yrs | 데이터 없음 | 0.065% $ 1.6m | |
| Senior VP of Legal | 1.3yrs | 데이터 없음 | 데이터 없음 | |
| Chief Legal Officer & Secretary | less than a year | 데이터 없음 | 데이터 없음 | |
| Vice President of Corporate Communications | 1.2yrs | 데이터 없음 | 데이터 없음 | |
| Vice President of Marketing | 1.2yrs | 데이터 없음 | 데이터 없음 | |
| Chief People Officer | 1.3yrs | 데이터 없음 | 데이터 없음 | |
| Executive Vice President of Development Operations | 6.2yrs | 데이터 없음 | 데이터 없음 |
2.1yrs
평균 재임 기간
53yo
평균 나이
경험이 풍부한 관리: VERA의 경영진은 경험이 있음으로 간주됩니다(평균 재임 2.1 년).
이사회 구성원
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| Founder | 10yrs | US$6.99m | 0.43% $ 10.7m | |
| Independent Director | 5.6yrs | US$346.66k | 0% $ 0 | |
| Independent Chairman of the Board | 4yrs | US$386.66k | 0% $ 0 | |
| Independent Director | 5.6yrs | US$351.66k | 0.0082% $ 201.9k | |
| Independent Director | 9.9yrs | US$346.66k | 0.19% $ 4.7m | |
| Independent Director | less than a year | 데이터 없음 | 0% $ 0 | |
| Independent Director | 6.1yrs | US$356.66k | 0% $ 0 | |
| Independent Director | less than a year | US$740.64k | 0% $ 0 | |
| Independent Director | 9yrs | US$344.16k | 0.024% $ 600.7k | |
| Independent Director | 1.9yrs | US$341.66k | 0.0042% $ 102.6k | |
| Independent Director | 4.4yrs | US$344.16k | 0% $ 0 |
5.6yrs
평균 재임 기간
58yo
평균 나이
경험이 풍부한 이사회: VERA의 이사회는 경험이 있음으로 간주됩니다(평균 재임 5.6 년).
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/22 11:15 |
| 종가 | 2026/05/22 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Vera Therapeutics, Inc.는 17명의 분석가가 다루고 있습니다. 이 중 11명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Dina Ramadane | BofA Global Research |
| Pete Stavropoulos | Cantor Fitzgerald & Co. |
| Gavin Clark-Gartner | Evercore ISI |